Join 1363 founders getting motivational stories of how other founders started and grew their online businesses

Hillstream BioPharma: A Breath of Fresh Air in Cancer Treatment


Giving cancer a taste of its own bitter medicine, Hillstream BioPharma is in it for the long run!

Currently, humanity is facing one of the most serious and deadly diseases - cancer. Even though some rare forms of cancer date back to ancient times, new ones are constantly being discovered, making cancer a modern-day issue.

However, one problem seems to regularly exist, and that’s the insufficiency of science and cutting-edge technology needed for the treatment of cancer-diseased patients. That changed when Chester, New Jersey became richer by another company promising to battle cancer. Randy Milby established Hillstream BioPharma in 2017, bringing a ray of hope to many.

Businessman Randy Milby saw the opportunity to experiment and develop new formulas for anti-cancer medication through Hillstream BioPharma, and that’s the main reason he created the company.

Stay with us to know more about what led Randy to the creation of the company that’s a breath of fresh air for many.

Young Inventor

Randy has always been quiet and private about his background and where he comes from. He was born in 1954 in New Jersey, the U.S.A, the place where he spent his childhood and high school days. Among his childhood friends, he was known to have a very creative mind and an enthusiastic personality, approaching each matter with a certain dose of curiosity.

During high school, Randy participated in a few group and solo projects in the field of business and entrepreneurship, showing some outstanding qualities. Even as a young boy, Randy was eager for changes, and wanted to use his ambitious and communicative nature to achieve what he planned.

In 1976, young Randy joined the University of Kansas, geared up on ambition to study pharmacy. After high school, he decided that even if he becomes an entrepreneur one day, it would be in the pharmaceutical field.

A few years later, after he earned himself a bachelor’s degree from the University of Kansas, Randy decided to attend yet a second college. He enrolled in Washington University in St. Louis, broadening his knowledge in finance and marketing. In 1985, he attained his master’s degree in Business and was ready to take on the world.

Becoming a Pharmaceutical Professional

An interesting fact about Randy is that he started his career in the US Army, but as a captain whose job was to distribute the medications in the army hospital. After obtaining his MBA, Randy was ready and willing to take a job in Bristol-Myers Squibb, where he was responsible for market research and product development of various antidepressants.

In the following years, Randy switched between various jobs; he worked in The Mattson Jack Group where he participated in technology assessment, strategic planning, and development of new medication needed for serious diseases.

Randy’s first major job was at DuPont Merck Pharmaceuticals in 1991, where he served as Senior Director. During this time in the firm, the pharmaceutical Goliath had grown into a billion-dollar company, thanks to Randy’s input in the development of blood pressure-lowering chemicals that hit the global market. Randy also helped expand the firm from the US to Europe in only 6 years.

Later on, he continued working at DuPont as a Global Business Director for the next 6 years. Randy was responsible for the company's re-enlistment into the medical sector through the use of material science capabilities.

In 2010, Randy became a founding partner at yet another pharmaceutical company, WaterStone Bridge. Garnering successes, Randy earned himself the title of CEO and member of the Board of Directors of CorMedix. It’s a publicly listed biopharmaceutical company focusing on discovering and commercializing therapeutic medicines for the treatment of inflammatory and infectious illnesses.

He guided Cormedix's market valuation from $3M to an amazing $350M while enhancing the company's financial situation through stock market capital raising. We can surely say that in his 40+ year career, Randy has gained substantial knowledge in many fields, undoubtedly becoming an exceptional expert in pharmaceuticals.

The Evolution of Hillstream BioPharma

After his vast previous professional experience, Randy decided to create his own biopharmaceutical company which would help patients with rare types of cancer. The official launch of Hillstream BioPharma happened in 2017, and it made a big boom, immediately.

Hillstream BioPharma, as a biotechnology platform, focuses on developing an innovative treatment that targets ferroptosis, a promising potential anti-cancer mechanism that results in iron-mediated cell death for drug-resistant and lethal malignancies.

HSB-1216, an IMCD modulator that targets a range of solid tumors, is Hillstream's most advanced contender. In clinical pilot research in Germany, the active medication in HSB-1216 was proven to be effective in deadly tumors such as triple-negative breast cancer and epithelial cancer.

The company uses Quatramer, a patented and unique tumor-targeting technology, to improve HSB-1216 absorption in the tumor microenvironment with a longer duration of action and fewer mishit effects.

The Quatramer can be tweaked and altered to deliver single or numerous payload ratios to improve synergistic modes of action in lower dosages in order to destroy uncommon malignancies and treatment-resistant tumors with few or no treatment alternatives.

Furthermore, Hillstream's artificial intelligence precision medicine platform, Trident Artificial Intelligence, is utilized to uncover biomarkers in order to target a specific patient segment most likely to benefit. Trident AI strives to fulfill the promise of precision medicine by establishing a platform built on the solid foundation of patient-driven biomarker research and deep learning artificial intelligence technology.

The product pipeline includes DNA-based components that seize cancer's genetic code and destroy it from within by creating a number of cancer-killing cytokines such as the main one called TNF-alpha, among others.

Unlike other similar companies, Hillstream BioPharma has proven to be very efficient in what it targets, and in the first couple of years since its existence. Some of Hillstream BioPharma’s main competitors include Leap Therapeutics, Neuren Pharmaceuticals, and Cancer Prevention Pharmaceuticals, however, none of them are nearly as inventive and efficient as Hillstream.

Financial Roundabouts

On January 12, 2022, Hillstream BioPharma raised a not-so-shabby amount of $15M just by issuing $3.8M shares for $4, much below the range between $5 and $6. The corporation provided $0.8M in more shares than what was expected.

Today, the company enjoys a market worth of $44M based on current prices, and the number goes up every year. Hillstream BioPharma will be omitted from Renaissance Capital's statistics since its IPO market value was less than $50M.

The leadership team consists of 7 exceptional professionals along with the 7 members of the Scientific Advisory Board. The whole team counts many more employees that equally contribute to the overall success of the company.

Working for a Healthier Future

Since Hillstream BioPharma’s founder, Randy, always had a passion and fascination for drug discovery, we are glad that he realized his dreams and made a platform that has already helped many people in their cancer treatment.

The fantastic New Jersey-based biotech platform that aims to enhance the life of every patient suffering from a rare kind of cancer and diseases alike is more than appreciated nowadays.

Randy is currently working on an experiment regarding cell line data. Hillstream Pharmaceuticals is working on a unique proprietary nanoparticle formulation of bortezomib, at the existing FDA-approved dosage.

The whole idea of what Randy wants to achieve is still not fully formed, however, they have only recently begun experimenting on mice and treating them.

Given the overall work of Hillstream BioPharma as a company and Randy as its inventor so far, we hope that this experiment will soon prove to be yet another victory in a series of successes.

By using innovative anti-cancer instruments, artificial intelligence medicine, and modern technology to quickly identify and treat lethal illnesses, Randy’s Hillstream BioPharma is surely here to stay, and we couldn't feel better knowing there’s someone working for a healthier future for all of us.